Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer
- VernacularTitle:贝莫苏拜单抗联合安罗替尼和化疗方案一线治疗广泛期小细胞肺癌的成本-效用分析
- Author:
Bing FENG
1
;
Ning GAO
1
;
Shengnan GAO
2
;
Yuxi ZHANG
1
;
Ranran ZHANG
1
;
Guoqiang LIU
1
Author Information
1. Dept. of Clinical Pharmacy，Hebei Medical University Third Hospital，Shijiazhuang 050051，China
2. Hebei Provincial Association for Comprehensive Evaluation of Medicines and Health Technologies，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
benmelstobart;
anlotinib;
extensive-stage small cell lung cancer;
partitioned survival model;
cost-utility analysis
- From:
China Pharmacy
2025;36(5):579-583
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-utility of benmelstobart combined with anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer （ES-SCLC） from the perspective of China’s healthcare system. METHODS Based on the data from the ETER 701 study， a partitioned survival model was constructed with a cycle of 3 weeks to simulate the total cost， quality-adjusted life years （QALY）， and incremental cost-effectiveness ratio （ICER） over 10 years for patients with ES- SCLC treated with benmelstobart plus anlotinib and chemotherapy， or chemotherapy alone. One-way sensitivity analysis and probability sensitivity analysis were performed to verify the robustness of the simulation results. The willingness-to-pay （WTP） threshold was set at 3 times the per capita gross domestic product （GDP） of China in 2023， which amounted to 268 074 yuan/QALY. RESULTS Compared with chemotherapy alone， benmelstobart combined with anlotinib and chemotherapy gained 0.438 QALY more at the cost of 403 505.55 yuan more， with an ICER of 922 031.37 yuan/QALY， which was higher than the WTP threshold set in this study. One-way sensitivity analysis showed that benmelstobart’s cost and utility value of the progression-free survival state had a greater impact on the ICER value； probabilistic sensitivity analysis confirmed the robustness of the model； only when the price of benmelstobart was reduced by 75.4%， the combined regimen would be cost-effective. CONCLUSIONS The first-line treatment of ES-SCLC with benmelstobart combined with anlotinib and chemotherapy is not cost-effective from the perspective of China’s healthcare system at present.
